远处转移灶而非配对原发尿路上皮癌的空间免疫表型可预测免疫检查点抑制剂应答
本研究在154例转移性尿路上皮癌患者(138对配对原发/转移灶)中检测PD-L1、空间免疫表型和MHC-I,发现配对原发/转移灶间不一致率分别为25/30%、36%和49%。转移灶免疫表型和MHC-I与化疗及ICI应答相关,而原发灶不相关;细胞毒性肿瘤免疫微环境患者ICI疾病控制率90%,进展/死亡HR 0.05(95%CI 0.01-0.65)。
要点
- 配对原发/转移灶PD-L1(CPS10/IC5%)、免疫表型、MHC-I不一致率分别为25/30%、36%、49%。
- 转移灶免疫表型和MHC-I与化疗及ICI应答相关,原发灶不相关。
- 细胞毒性TIME的MET患者ICI疾病控制率90%,进展/死亡HR 0.05(95%CI 0.01-0.65)。
核心结论
- 肿瘤免疫微环境在转移演化过程中发生显著动态变化,转移灶免疫表型和MHC-I状态有潜力预测化疗和持久ICI应答,而原发灶TIME不能。
- 未来临床试验应依赖反映当前免疫疾病状态的预处理转移灶活检而非原发灶。
研究设计与样本
- 在154例转移性尿路上皮癌患者中检测PD-L1、空间免疫表型和MHC-I,其中138对为患者配对的原发/转移灶。
- 将配对原发灶和预处理转移灶的PD-L1、空间免疫表型及MHC-I状态与化疗和ICI应答及结局进行相关性分析。
主要发现
- 配对原发/转移灶间PD-L1(CPS10/IC5%)、免疫表型、MHC-I(缺失vs保留)的不一致率分别为25/30%、36%、49%。
- 转移灶(而非原发灶)中确定的免疫表型和MHC-I状态与化疗和ICI应答相关,PD-L1单独不相关。
- ICI治疗中,细胞毒性肿瘤免疫微环境(TIME)患者疾病控制率90%,疾病进展/死亡风险比0.05(95%CI 0.01-0.65),对比免疫缺失转移灶患者疾病控制率29%。
- 转移灶MHC-I状态对预测持久ICI应答具有增量价值。
临床怎么用
- 作者认为,未来临床试验应依赖预处理转移灶活检反映当前免疫疾病状态,而非原发灶。
局限性
- 部分为回顾性设计。
- 缺乏个体患者层面的转移灶多次采样。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The value of programmed cell death ligand-1 (PD-L1) to predict durable responses to immune checkpoint inhibitors (ICIs) in metastatic urothelial carcinoma (mUC) is inconsistent. We hypothesize that the use of archived primary tumor material (PRIM) for PD-L1 testing in clinical trials not properly reflecting the metastatic disease status (MET) contributes to this clinical issue. OBJECTIVE: To analyze the predictive and prognostic value of PD-L1, spatial immunephenotypes, and major histocompatibility complex class I (MHC-I) determined in patient-matched PRIM/MET. DESIGN, SETTING, AND PARTICIPANTS: PD-L1, spatial immunephenotypes, and MHC-I were examined in 154 mUC patients with at least one available pretreatment MET (138 patient-matched PRIM/MET pairs). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: PD-L1, spatial immunephenotype, and MHC-I status of (patient-matched PRIM and) pretreatment MET were correlated with chemotherapy and ICI response and outcomes. RESULTS AND LIMITATIONS: Discordance rates in patient-matched PRIM/MET were 25/30%, 36%, and 49% for PD-L1 (CPS10/IC5%), immunephenotypes, and MHC-I (loss vs preserved), respectively. Correlations with chemotherapy and ICI responses were observed for immunephenotypes and MHC-I status determined in MET (not for PD-L1 alone), but not in PRIM. In case of ICIs, patients with cytotoxic tumor immune microenvironment (TIME) showed durable responses with disease control rates of 90% and a hazard ratio for disease progression/death of 0.05 (95% confidence interval: 0.01-0.65) versus patients with immunedepleted MET (disease control rate 29%). MET MHC-I status added an incremental value to predict durable ICI responses. Limitations include the partly retrospective design and the lack of MET multisampling on individual patient level. CONCLUSIONS: The TIME is subject to substantial dynamics during metastatic evolution. MET immunephenotypes and MHC-I statuses show promising potential to predict chemotherapy and durable ICI responses, while the PRIM TIME does not. Thus, future clinical trials should rather rely on pretreatment MET biopsies reflecting the current immunological disease state than on PRIM. PATIENT SUMMARY: Prediction of chemotherapy and responses to immune checkpoint inhibitors might be possible using representative pretreatment metastatic biopsies.
引用
- Erlmeier F, Klümper N, Landgraf L, et al. Spatial Immunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint Inhibition. Eur Urol. 2022. PMID: 36372626. doi:10.1016/j.eururo.2022.10.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。